Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director

Cullinan Therapeutics, Inc.

2024-Q1 EPS reported -$0.86

Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.
Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.
CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.
David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.
Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Meek

Class I Director

CGEM · Cullinan Therapeutics, Inc.

Effective: 2024-05-15
Filed: May 15, 2024, 7:59 PM ET

the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.

Departed

Thomas Ebeling

Director

CGEM · Cullinan Therapeutics, Inc.

Effective: 2024-06-26
Filed: May 15, 2024, 7:59 PM ET

Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million
Result: reported results

Exact text from the filing

Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.